Patent ID: 9402844
Filing Date: 2016-08-02
CPC Classification: A61K

Claim Text:
1. A method of increasing dextromethorphan plasma levels in a human being, comprising co-administering erythrohydroxybupropion with dextromethorphan to the human being for at least eight consecutive days, wherein the human being is an extensive metabolizer of dextromethorphan in need of treatment with dextromethorphan, wherein erythrohydroxybupropion and dextromethorphan are the sole active agents administered to the human being, wherein the erythrohydroxybupropion is administered in an amount that results in an AUC 0-12 of dextromethorphan that is at least about 40 ng·hr/mL, and wherein, on the eighth day that erythrohydroxybupropion and dextromethorphan are co-administered, the AUC 0-12 of dextromethorphan is at least about 20 times the AUC 0-12 of dextromethorphan that would result from administering the same amount of dextromethorphan without erythrohydroxybupropion.